NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen declared that its Board of Directors has approved a stock buyback program on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Biogen Inc (NASDAQ:BIIB) announced its earnings results on Tuesday, October, 22nd. The biotechnology company reported $9.17 earnings per share for the quarter, beating the Zacks' consensus estimate of $8.27 by $0.90. The biotechnology company had revenue of $3.60 billion for the quarter, compared to analysts' expectations of $3.53 billion. Biogen had a return on equity of 46.14% and a net margin of 37.91%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business earned $7.40 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Biogen.

Biogen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

34 analysts have issued 12-month price targets for Biogen's stock. Their forecasts range from $230.00 to $365.00. On average, they anticipate Biogen's share price to reach $288.72 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Biogen.

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 21 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

Media coverage about BIIB stock has trended very positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biogen earned a coverage optimism score of 3.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Boeing (BA).

Biogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.26%), Candriam Luxembourg S.C.A. (0.22%), Tocqueville Asset Management L.P. (0.08%), Wedge Capital Management L L P NC (0.07%), DNB Asset Management AS (0.06%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Candriam Luxembourg S.C.A., Artemis Investment Management LLP, Gateway Investment Advisers LLC, Wedge Capital Management L L P NC, Country Trust Bank and OLD National Bancorp IN. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Rhenman & Partners Asset Management AB, Alpine Global Management LLC, Abner Herrman & Brock LLC, Ballentine Partners LLC, Wealthfront Advisers LLC, Baxter Bros Inc. and FormulaFolio Investments LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $284.21.

Biogen has a market capitalization of $51.28 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.View Additional Information About Biogen.

The official website for Biogen is http://www.biogen.com/.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]